PRNewsWire
17 Nov 2026, 03:17 UTC · 56m ago
Five-year data of continuous Leqembi® treatment show increasing benefit over time
Impact · against what's priced in
The five-year data provides a fundamental catalyst for BIIB by validating the long-term durability and efficacy of Leqembi, strengthening the bull case for the drug's lifetime value per patient. While the news is positive, it primarily supports the overarching growth potential of the product rather than the specific delivery-method catalysts the market is currently waiting for.
- BIIB+0.30
Challenges what's priced in
- The price assumes





